Q BioMed Inc.

Equities

QBIO

US74736N1054

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:19:11 31/05/2024 BST			5-day change	1st Jan Change
0.0006 ^USD	+50.00%		+500.00%	+50.00%

2023	Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	CI
2023	Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	CI

Q Biomed Inc. Reports Earnings Results for the Third Quarter Ended August 31, 2020

October 14, 2020 at 09:59 pm

Q BioMed Inc. announced earnings results for the third quarter ended August 31, 2020. For the third quarter, the company announced sales was USD 15,000. Operating loss was USD 2.248 million compared to USD 1.754 million a year ago. Net loss was USD 2.257 million compared to USD 2.546 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.17 a year ago. For the nine months, sales was USD 30,000. Operating loss was USD 9.719 million compared to USD 6.079 million a year ago. Net loss was USD 10.062 million compared to USD 7.809 million a year ago. Basic loss per share from continuing operations was USD 0.5 compared to USD 0.54 a year ago.

Latest news about Q BioMed Inc.

Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	16/06/23	CI
Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	26/05/23	CI
Q BioMed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent from United States Patent Office	10/02/23	CI
Q BioMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	03/11/22	CI
Q BioMed Inc. Announces Issuance of Patent for Groundbreaking Gdf15 Biomarker	27/09/22	CI
Q BioMed Inc. Reports Second Quarter Revenues in 2022	29/07/22	CI
Q BioMed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	28/07/22	CI
Q BioMed Inc. Announces Publication of Pre-Clinical Research Showing Superior Safety and Efficacy Against Current First Line Therapy of Its Drug Candidate Uttroside-B for Liver Cancer	26/07/22	CI
Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2022	14/04/22	CI
Q BioMed Inc. Announces Publication of Research Showing Augmented Efficacy of its Drug Candidate Uttroside-B Against Liver Cancer	16/03/22	CI
Q BioMed Inc. Announces Initial $500,000 Order of Strontium89 to Chinese Market	07/03/22	CI
Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2021	28/02/22	CI
Q BioMed Inc. Auditor Raises 'Going Concern' Doubt	27/02/22	CI
Q BioMed Inc. Bolsters Commercialization of Strontium89 with EVERSANA Partnership	08/11/21	CI
Q Biomed Inc. Reports Earnings Results for the Third Quarter Ended August 31, 2021	15/10/21	CI
Q BioMed Inc. announced that it has received $2.015 million in funding from GS Capital Partners LLC	04/10/21	CI
Q BioMed Inc. announced that it expects to receive $2.015 million in funding from GS Capital Partners LLC	28/09/21	CI
Q Biomed Inc. Updates on Covid-19 Therapeutic Development and Clinical Trials - Man-19 Therapeutic Program Heading to Clinical Trial in Early 2022	22/09/21	CI
Q Biomed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent in South Korea and Shows Positive Results in Initial Pre-Clinical Testing	24/08/21	CI
Q BioMed Inc. Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada	10/08/21	CI
Q BioMed Inc. announced that it has received $0.75 million in funding from Platinum Point Capital LLC	25/07/21	CI
Q Biomed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East	12/07/21	CI
Q BioMed Inc. announced that it expects to receive $20 million in funding from Aedesius Holdings Ltd	04/05/21	CI
Q Biomed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2021	14/04/21	CI
Q Biomed Awards Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs	02/03/21	CI

Chart Q BioMed Inc.

Duration

Period

More charts

Company Profile

Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Companyâs pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. QBM-001 is designed to alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disabilities caused from being non-verbal. Uttroside-B is a potential chemotherapeutic for liver cancer. Its primary indication, MAN-01, is for the treatment of primary open angle glaucoma, wherein it is developing a small molecule in the form of an easy to administer eye drop to reduce intra-ocular eye pressure (IOP), a key risk factor in the progression of glaucoma.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
Q BIOMED INC.	+50.00%	87.06K
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	123B
REGENERON PHARMACEUTICALS, INC.	+13.04%	107B
BIONTECH SE	-5.80%	24.01B
ARGENX SE	+2.18%	22.59B
GENMAB A/S	-10.09%	18.16B
WUXI APPTEC CO., LTD.	-40.52%	16.84B
BEIGENE, LTD.	-14.00%	16.23B
NEUROCRINE BIOSCIENCES, INC.	+1.18%	13.43B
SAREPTA THERAPEUTICS, INC.	+24.18%	11.32B

Bio Therapeutic Drugs